Cidara Thera (CDTX) Stock Price, Quote & News

Company Profile

Cidara Therapeutics, Inc. operates as a biotechnology company that focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enab...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 752 6170

Website: www.cidara.com

Address:

6310 Nancy Ridge Drive, Suite 101, San Diego, United States

ElizabethEstebana Dec. 7 at 3:55 AM

$XRP.X $FMCC $AMRN $CDTX $CVKD Trend favors the upside.

1 · Reply

MaryDiaz Dec. 7 at 3:10 AM

"$INTC $AAPL $DBRG $CDTX Why Intel Stock Jumped Today Intel's move reveals a lot about where the company thinks it's headed. Intel keeps NEX unit, reversing divestment plans. Reports suggest Intel may resume making chips for Apple, sparking market speculation and volatility."

0 · Reply

King0ftheN0rth Dec. 7 at 2:59 AM

$CDTX hmm

0 · Reply

brambo13 Dec. 7 at 2:22 AM

$ALT $CDTX wow I’m so hot for that trend-line

0 · Reply

Geohotventures Dec. 7 at 1:58 AM

$ALT $CDTX that chart's a thing of beauty! 😍

1 · Reply

Wolly99 Dec. 6 at 11:09 PM

the $ALT chart looks so similar to $CDTX . could melt up to $25 due to positive results/Lancet publication/p3 design and then explode to $75 with a bo...bidding wars in MASH are crazy right now and GLP-1/GCGR agonists were hyped at AASLD last month

10 · Reply

Gps_100X_ROI_Potential Dec. 6 at 7:39 PM

$CDTX Ron has much good data, worth a Follow. I was going to repost his discussion the ESOP Plan automatic tax basis S4's -- and saw this, the below escalating BIG Pharma Buyout BIDDING for - looks like $MRK put the hammer down. 2 Points: 1. outside the auto Esop tax shares, No SLS Insider has EVER sold a single Share of Stock. - Not 1 - Ever. InSiders have actually BEEN BUYING On the OPEN Market AND in the Plan, with their own cash ... 2. $MRK Dr. Julie Cohen, in Co-Authoring the GPS Keytruda Phase 2 Data, stated they want to run a Phase 3 for solid tumors ... Gps+key achieved Better MOS 18.4 months than Elahere 16.46 mo / abbv bought IMGN for 10.1B. based on the Elahere data as Bullish Medspeak anyone will ever See. This is why Mrk and BMY are heavy contenders, along with PFE and ABBV - who's Aza+VEN, AML CR1 Maintenance Phase 3 VIALE-M Just FAILED. .. . pro tip: azaVEN is the BAT for the SLS Regal P3 about to report top line results, 5 years in the making, incoming THIS MONTH.

0 · Reply

RonIsWrong Dec. 6 at 7:18 PM

$CDTX How it went down

1 · Reply

Johnmtnb2018 Dec. 6 at 3:25 PM

$CDTX $SLS $MRK I have been trading in Biotechnology sector for over 35 years now. CDTX was my biggest win this year. As you can see in my post below on CDTX in 2023. I will also like to point out that Phase 3 ANCHOR trial for the CD388 influenza preventative (which is an antiviral, not a traditional vaccine) is still ongoing. Enrollment for the study has reached its target of 6,000 participants as of November 2025. An interim analysis is expected in the first quarter of 2026 to assess the results from the Northern Hemisphere flu season and determine if enrollment is needed in the Southern Hemisphere. So all the people here that think BO will come after the gps regal phase 3 study better take a look at Merck buy out of CDTX. Merck, through a subsidiary, will acquire Cidara for $221.50 per share in cash, for a total transaction value of approximately $9.2 billion. I won’t be surprised when the trading halts here at SLS and a buy out PR is released thereafter. Merry Christmas longs!

1 · Reply

bavariaron Dec. 6 at 1:33 AM

$VKTX ** Insight: Quiet Period is a Fantasy ** Bidding wars public and behind the scenes for mid to late stage biotechs. @Seedy19Tron on X about MRK—CDTX Acquisition: “You guys are gonna mute me at this rate , but so many takeaways. $CDTX literally had their earnings call on 11/07!!! I think gone are the days of ‘quiet period’ and CEOs dropping out of conferences.” $CDTX $MRK mergers details out 10/24 -$118 offer from company D 10/29- $120 offer from $MRK 11/01 - $130 offer from company D 11/04 - $104 offer from company E 11/07 - $150 offer from company D 11/08 - $156 offer from $MRK 11/08 - $140 offer from company F 11/08 - $127 + cvr offer from company E 11/11 - $158 offer from company E 11/11 - $165 offer from company F 11/13 - $173.5 offer from company E 11/13 - $185 offer from company F 11/13 - $221.5 offer from $MRK accepted 11/14 - announcement VKTX Absolutely

3 · Reply

Cidara Therapeutics Reaches Target Enrollment of Phase 3 ANCHOR Trial Evaluating CD388 for Prevention of Seasonal Influenza in High-Risk Populations

Nov 20, 2025, 9:48 AM EST - 16 days ago

Institutional Titan Hits the Jackpot: Biotech Stock Surges by 116% on Buyout Offer

Nov 20, 2025, 6:57 AM EST - 16 days ago

Cidara Therapeutics Is Up Over 100%. Here's What Investors Need to Know.

Nov 19, 2025, 1:05 PM EST - 17 days ago

Big Pharma Has Spent Nearly $150 Billion On M&A (So Far) In 2025

MRK

Nov 17, 2025, 10:37 AM EST - 19 days ago

This Fund Sold $49 Million of Cidara Stock — Then Merck Announced a $9.2 Billion Takeover

Nov 17, 2025, 8:34 AM EST - 19 days ago

Merck expects over $5 billion commercial opportunity from Cidara's flu drug

MRK

Nov 17, 2025, 8:15 AM EST - 19 days ago

Top 2 Health Care Stocks That May Fall Off A Cliff This Month

AVDL

Nov 16, 2025, 6:49 PM EST - 20 days ago

Cidara Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Cidara Therapeutics, Inc. - CDTX

MRK

Nov 14, 2025, 6:17 PM EST - 22 days ago

If M&A continues at this pace you want to be long Biotech into next year, says Mizuho's Jared Holz

IBB MRK XBI XLV

Nov 14, 2025, 4:25 PM EST - 22 days ago

This Biotech's Stock Price More Than Doubled on Friday. Here's Why.

Nov 14, 2025, 11:20 AM EST - 22 days ago

This is why Merck is buying Cidara Therapeutics for $9.2 billion, and why Wall Street is happy

MRK

Nov 14, 2025, 10:00 AM EST - 22 days ago

NVDA Price Target Hikes, STUB Shows No Guidance, MRK Buying CDTX

MRK NVDA STUB

Nov 14, 2025, 8:30 AM EST - 22 days ago

Merck to buy Cidara Therapeutics for $9.2 billion as Keytruda patent cliff approaches

MRK

Nov 14, 2025, 7:16 AM EST - 22 days ago

Merck to Buy Cidara Therapeutics in $9.2 Billion Deal

MRK

Nov 14, 2025, 6:51 AM EST - 22 days ago

Merck bets on flu prevention with about $9.2 billion deal for Cidara Therapeutics

MRK

Nov 14, 2025, 6:45 AM EST - 22 days ago

Merck to Acquire Cidara Therapeutics, Inc., Diversifying Its Portfolio to Include Late-Phase Antiviral Agent

MRK

Nov 14, 2025, 6:09 AM EST - 22 days ago

Wall Street Breakfast Podcast: Merck Talks Send Cidara Soaring

DASH MRK

Nov 13, 2025, 6:53 PM EST - 23 days ago

Merck nearing deal for Cidara, FT reports

MRK

Nov 7, 2025, 2:56 PM EST - 4 weeks ago

Cidara Therapeutics, Inc. (CDTX) Q3 2025 Earnings Call Transcript

Nov 6, 2025, 4:07 PM EST - 4 weeks ago

Cidara Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results

Oct 28, 2025, 8:00 AM EDT - 5 weeks ago

Cidara Therapeutics to Participate in November Investor Conferences

Oct 23, 2025, 4:05 PM EDT - 6 weeks ago

Cidara Therapeutics to Report Third Quarter 2025 Financial Results and Host Quarterly Conference Call on November 6, 2025

Oct 23, 2025, 8:00 AM EDT - 6 weeks ago

Cidara Therapeutics Announces Late-Breaking Presentation on CD388 at 10ᵗʰ ESWI Influenza Conference 2025

Oct 21, 2025, 12:52 PM EDT - 6 weeks ago

Cidara Therapeutics: A Potential Blockbuster In Flu Prevention

Oct 21, 2025, 8:00 AM EDT - 6 weeks ago

Cidara Therapeutics Announces Late-Breaking Phase 2b Data Presentation on CD388 at ID Week 2025

Oct 13, 2025, 8:00 AM EDT - 7 weeks ago

Cidara Therapeutics to Present Late-Breaking Clinical Phase 2 Data on CD388 at ID Week 2025

Oct 10, 2025, 8:00 AM EDT - 2 months ago

Cidara Therapeutics to Present at 10th ESWI Influenza Conference 2025

Oct 9, 2025, 6:32 PM EDT - 2 months ago

Why Cidara Therapeutics Stock Crushed It Today

Oct 9, 2025, 8:00 AM EDT - 2 months ago

Cidara Therapeutics Receives U.S. FDA Breakthrough Therapy Designation for CD388 in Seasonal Influenza Prevention

Oct 2, 2025, 4:01 PM EDT - 2 months ago

Cidara Therapeutics Announces BARDA Award to Support Expanded Manufacturing and Clinical Development of CD388, its Non-Vaccine Influenza Preventative Therapeutic

Sep 26, 2025, 5:09 PM EDT - 2 months ago

Why Cidara Therapeutics Was Such a Healthy Stock Today

Sep 25, 2025, 4:01 PM EDT - 2 months ago

Cidara Therapeutics Announces First Participants Dosed in Phase 3 ANCHOR Trial Evaluating CD388 for the Prevention of Seasonal Influenza in High-Risk Populations

Sep 24, 2025, 7:00 AM EDT - 2 months ago

Cidara Therapeutics Announces Expanded and Accelerated Phase 3 Plan for CD388, a Non-Vaccine Preventative of Seasonal Influenza

Sep 17, 2025, 8:00 AM EDT - 2 months ago

Cidara Therapeutics Presents Data on CD388 from its Phase 2b NAVIGATE Trial and Preclinical Studies Against H5N1 at ISRV's 8th AVG and 3rd IMRP 2025 Meeting

Sep 9, 2025, 12:41 PM EDT - 3 months ago

Cidara Therapeutics, Inc. (CDTX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 4, 2025, 8:00 AM EDT - 3 months ago

Cidara Therapeutics to Participate in September Investor Conferences

Sep 3, 2025, 8:00 AM EDT - 3 months ago

Cidara Therapeutics to Present Clinical Phase 2b Data and Preclinical H5N1 Data on CD388 at ISRV's 8th AVG and 3rd IMRP 2025 Meeting

Aug 15, 2025, 1:07 PM EDT - 4 months ago

Cidara Therapeutics: Still Big Catalysts Ahead Following Impressive Ph2b Readout

Aug 8, 2025, 6:04 PM EDT - 4 months ago

Cidara Therapeutics, Inc. (CDTX) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 4:37 PM EDT - 4 months ago

Cidara (CDTX) Q2 Cash Surges 163%

Aug 7, 2025, 4:05 PM EDT - 4 months ago

Cidara Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results

Jul 24, 2025, 8:00 AM EDT - 4 months ago

Cidara Therapeutics to Report Second Quarter 2025 Financial Results and Host Quarterly Conference Call on August 7, 2025

Jul 7, 2025, 1:00 PM EDT - 5 months ago

Segal Trials Contributes to Breakthrough Flu Prevention Study Led by Cidara Therapeutics

Jul 1, 2025, 4:59 PM EDT - 5 months ago

Cidara Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Jun 30, 2025, 8:00 AM EDT - 5 months ago

Cidara Therapeutics Announces Inclusion in the Russell 2000® and Russell 3000® Indexes

Jun 26, 2025, 5:15 PM EDT - 5 months ago

Cidara Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

Jun 25, 2025, 7:30 AM EDT - 5 months ago

Cidara Therapeutics Advances CD388 To Phase 3, Reiterate Buy

Jun 24, 2025, 8:00 PM EDT - 5 months ago

Cidara Announces Pricing of Upsized Public Offering of Common Stock

ElizabethEstebana Dec. 7 at 3:55 AM

$XRP.X $FMCC $AMRN $CDTX $CVKD Trend favors the upside.

1 · Reply

MaryDiaz Dec. 7 at 3:10 AM

0 · Reply

King0ftheN0rth Dec. 7 at 2:59 AM

$CDTX hmm

0 · Reply

brambo13 Dec. 7 at 2:22 AM

$ALT $CDTX wow I’m so hot for that trend-line

0 · Reply

Geohotventures Dec. 7 at 1:58 AM

$ALT $CDTX that chart's a thing of beauty! 😍

1 · Reply

Wolly99 Dec. 6 at 11:09 PM

10 · Reply

Gps_100X_ROI_Potential Dec. 6 at 7:39 PM

0 · Reply

RonIsWrong Dec. 6 at 7:18 PM

$CDTX How it went down

1 · Reply

Johnmtnb2018 Dec. 6 at 3:25 PM

1 · Reply

bavariaron Dec. 6 at 1:33 AM

3 · Reply

TwongStocks Dec. 5 at 10:16 PM

$CDTX Tender offer filed with the SEC https://www.sec.gov/Archives/edgar/data/310158/000119312525309877/d78449dsctot.htm • $MRK tender offer is $221.50 for each common share of CDTX and $15,505 for each Series A preferred share. • Tender offer expires one minute following 11:59 p.m., Eastern Time, on January 6, 2026, unless extended or earlier terminated.

0 · Reply

BillionerOfKing Dec. 5 at 3:10 PM

$CDTX Current Stock Price: $220.62 Contracts to trade: $220 CDTX Dec 19 2025 Call Entry: $0.05 Exit: $0.10 ROI: 94% Hold ~28 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

stockanalysis_ Dec. 5 at 1:07 AM

Overbought Stocks: $MAGH $SND $HAE $EXAS $CDTX View the entire list here: https://stockanalysis.com/list/overbought-stocks/?ref=saveontrading

0 · Reply

Sarandon Dec. 4 at 3:58 PM

$SGBX I already warned you yesterday, a sharp rise was very likely. $CHRS next Monster runner?🚨 This share is highly undervalued and has a high probability of being acquired. Its cash (194 millions) reserves exceed its market cap (155 millions) This November, Day One Biopharmaceuticals acquired Mersana Therapeutics ($MRSN), Merk ($MERK.X) acquired Cidara Therapeutics ($CDTX),..... The sector is on fire 🔥🔥🚀 ¿December? ¿BOOM?🔥💯

0 · Reply

TAG01 Dec. 4 at 2:08 PM

$CDTX I have been in alot of BO.. never have they traded so close to the BO number so far away from closing. something is amiss. possibly another bidder. even a few shares above 221 traded.

1 · Reply

SuperPuncher Dec. 3 at 7:20 PM

$ALT $CDTX $MRK BUUUULLLIIISHHHH

0 · Reply

Kass987 Dec. 3 at 3:17 PM

$CDTX board has been dead . Is this pretty mych done until we hear on PH 3?

1 · Reply

Nebler Dec. 3 at 12:47 PM

$IFRX theory: Someone wants a RS and get in after heavy like RA Capital did on $CDTX (after a 20:1 reverse split). Ended pretty well for them with a massive return in no time..

1 · Reply

Sarandon Dec. 2 at 2:48 PM

$CHRS This share is highly undervalued and has a high probability of being acquired. Its cash (194 millions) reserves exceed its market cap (153 millions) This November, Day One Biopharmaceuticals acquired Mersana Therapeutics ($MRSN), Merk ($MERK.X) acquired Cidara Therapeutics ($CDTX),..... The sector is on fire 🔥🔥🚀 ¿December? ¿BOOM?🔥💯

0 · Reply

Sarandon Dec. 1 at 3:02 PM

$CHRS This stock is highly undervalued and has a high probability of being acquired. Its cash (193 millions) reserves exceed its market cap (154 millions) This November, Day One Biopharmaceuticals acquired Mersana Therapeutics ($MRSN), Merk ($MERK.X) acquired Cidara Therapeutics ($CDTX),..... The sector is on fire 🔥🔥🚀 ¿December? ¿BOOM?

0 · Reply

Sarandon Nov. 28 at 4:43 PM

$CHRS This stock is highly undervalued and has a high probability of being acquired. Its cash (192 millions) reserves exceed its market cap (155 millions) This November, Day One Biopharmaceuticals acquired Mersana Therapeutics ($MRSN), Merk ($MERK.X) acquired Cidara Therapeutics ($CDTX),..... The sector is on fire 🔥🔥🚀

1 · Reply

Texout Nov. 27 at 11:01 AM

$VNDA just to clarify for the more inpatient community. This is not a blockbuster story trade like $CDTX has been. This is a deep-value + litigation + optionality trade. High net cash vs market cap — historically a reason deep-value funds pay attention. • Real revenue base (Hetlioz, Fanapt). • Pipeline assets (tradipitant, gastroparesis) have non-zero upside if management executes. What suppresses it • Management historically fights activist investors. • IP battles + FDA politics+ Marketing Spend • Not a momentum stock → perfect for patient deep-value funds. That’s why bought tons sub 5$ Will revisit once we pass 10$ and make up my targets. Nice weekend

0 · Reply

Market Cap	6.93B
Revenue (ttm)	1.28M
Net Income (ttm)	-169.83M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-13,267.97%
Debt to Equity Ratio	0.00

Volume	661,800
Avg Vol	1,522,844
Day's Range	N/A - N/A
Shares Out	31.44M
Stochastic %K	61%
Beta	1.46
Analysts	Sell
Price Target	$195.25